Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,615
datasets available to search
ShareScore release 0.9.0
Dataset results
2,615 results for “HIV Infections”
Dataset of 'HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin Lymphoma'
<p><span><span>§<span> </span></span></span><strong><span>:</span></strong><span>The data were generated using the i) GeoMx Digital Spatial Profiler (DSP) platform developed by Nanostring Technologies. GeoMx analysis utilizes <em>in situ </em>RNA hybridization with Whole Atlas Transcriptome probe (Nanostring) and ii) HTG platform (Immune Response kit) Our dataset comprises samples from donors categorized as HLposHIVnegEBVneg, HLposHIVposEBVpos, or HLposHIVnegEBVpos (HL: Hodgkin Lymphoma). Regions of interest (ROI) were spatially profiled to capture distinct molecular signatures associated with these donor categories.</span></p>
Dataset of "Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-infected Cells"
<p><strong>Detailed quantitative analysis of GFP expression in SAHA and TCR-treated cells & Computational analysis of bulk and single-cell RNA-Seq data.</strong></p> <p> </p> <p><em><strong>Detailed quantitative analysis of GFP expression in SAHA and TCR-treated cells.</strong></em></p> <p>Cells were prepared for single cell analysis at the Genome Technology Facility (GTF) of the University of Lausanne. Cells were loaded on Fluidigm C1 IFC plates (5-10 μm), with run ID smart33, smart34 and smart35, corresponding to untreated, SAHA- and TCR-treated conditions respectively. After single cell capture on the Fluidigm C1 IFC plate, each chamber was inspected visually by microscopy and pictures were captured with a Zeiss Axiovert 200 M fluorescence microscope equipped with a Roper Scientific CoolSnap HQ camera using a Plan-Neofluar 10X lens (smart34 run) or 20X lens (for smart35 run). For each capture chamber, pictures in bright field and FITC channel were taken with the MetaMorph 6.3 software. Picture analysis was then performed using ImageJ 1.50b software (open access software: website). Brightness and contrast were adjusted for qualitative assessment of the pictures.</p> <p><em><strong>Computational analysis of bulk and single-cell RNA-Seq data.</strong></em></p> <p>Upon bulk or single cell isolation, RNA extraction and library preparation was performed according to Illumina protocols. Bulk and single-cell RNA-Seq data analysis are detailed here.</p> <p> </p> <p>Linked to the paper published in Cell Reports (doi:10.1016/j.celrep.2018.03.102): </p> <p><strong>Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-infected Cells</strong></p> <p>Despite effective treatment, HIV can persist in latent reservoirs, which represent a major obstacle towards HIV eradication. Targeting and reactivating latent cells is challenging due to the heterogeneous nature of HIV infected cells. Here, we used a primary model of HIV latency and single-cell RNA sequencing to characterize transcriptional heterogeneity during HIV latency and reactivation. Our analysis identified transcriptional programs leading to successful reactivation of HIV expression.</p> <p> </p> <p> </p>
Dataset: Knowledge, information needs and behavior regarding HIV and sexually transmitted infections among migrants from sub-Saharan Africa living in Germany: Results of a participatory health research survey.
<p>Dataset for: Koschollek C, Kuehne A, Müllerschön J, Amoah S, Batemona-Abeke H, Dela Bursi T, Mayamba P, Thorlie A, Mputu Tshibadi C, Wangare Greiner V, Bremer V, Santos-Hövener C: Knowledge, information needs and behavior regarding HIV and sexually transmitted infections among migrants from sub-Saharan Africa living in Germany: Results of a participatory health research survey.</p> <p>This dataset has been described in a PLoS One paper and contains all data necessary to replicate the results presented within this paper (10.1371/journal.pone.0227178). Please cite both the paper as well as the DOI of this dataset if you make use of the data.</p>
RNAseq sequences of the study "Transactive response DNA-binding Protein (TARDBP/TDP-43) regulates early HIV-1 entry and infection" (1/2)
<p>Each pair of FASTQ files corresponds to a specific sample condition:</p> <table> <thead> <tr> <th scope="col">Condition</th> <th scope="col">Sample</th> <th scope="col">FASTQ name R1</th> <th scope="col">FASTQ name R2</th> </tr> </thead> <tbody> <tr> <td>Cneg</td> <td>RNASEQ-AVF1</td> <td>RNASEQ-AVF1_S1_R1_001.fastq.gz</td> <td>RNASEQ-AVF1_S1_R2_001.fastq.gz</td> </tr> <tr> <td>Flag-wt-TDP-43</td> <td>RNASEQ-AVF2</td> <td>RNASEQ-AVF2_S2_R1_001.fastq.gz</td> <td>RNASEQ-AVF2_S2_R2_001.fastq.gz</td> </tr> <tr> <td>Flag-NLS-mut-TDP-43</td> <td>RNASEQ-AVF3</td> <td>RNASEQ-AVF3_S3_R1_001.fastq.gz</td> <td>RNASEQ-AVF3_S3_R2_001.fastq.gz</td> </tr> <tr> <td>Cneg</td> <td>RNASEQ-AVF4</td> <td>RNASEQ-AVF4_S4_R1_001.fastq.gz</td> <td>RNASEQ-AVF4_S4_R2_001.fastq.gz</td> </tr> <tr> <td>Scramble</td> <td>RNASEQ-AVF5</td> <td>RNASEQ-AVF5_S5_R1_001.fastq.gz</td> <td>RNASEQ-AVF5_S5_R2_001.fastq.gz</td> </tr> <tr> <td>TDP-43 siRNA A</td> <td>RNASEQ-AVF6</td> <td>RNASEQ-AVF6_S6_R1_001.fastq.gz</td> <td>RNASEQ-AVF6_S6_R2_001.fastq.gz</td> </tr> <tr> <td>TDP-43 siRNA B</td> <td>RNASEQ-AVF7</td> <td>RNASEQ-AVF7_S7_R1_001.fastq.gz</td> <td>RNASEQ-AVF7_S7_R2_001.fastq.gz</td> </tr> <tr> <td>TDP-43 siRNA C</td> <td>RNASEQ-AVF8</td> <td>RNASEQ-AVF8_S8_R1_001.fastq.gz</td> <td>RNASEQ-AVF8_S8_R2_001.fastq.gz</td> </tr> </tbody> </table> <p> </p>
RNAseq sequences of the study "Transactive response DNA-binding Protein (TARDBP/TDP-43) regulates early HIV-1 entry and infection" (2/2)
<p>Each pair of FASTQ files corresponds to a specific sample condition:</p> <table> <thead> <tr> <th scope="col">Condition</th> <th scope="col">Sample</th> <th scope="col">FASTQ name R1</th> <th scope="col">FASTQ name R2</th> </tr> </thead> <tbody> <tr> <td>TDP-43 siRNA D</td> <td>RNASEQ-AVF9</td> <td>RNASEQ-AVF9_S1_R1_001.fastq.gz</td> <td>RNASEQ-AVF9_S1_R2_001.fastq.gz</td> </tr> <tr> <td>Cneg</td> <td>RNASEQ-AVF10</td> <td>RNASEQ-AVF10_S2_R1_001.fastq.gz</td> <td>RNASEQ-AVF10_S2_R2_001.fastq.gz</td> </tr> <tr> <td>Flag-wt-TDP-43</td> <td>RNASEQ-AVF11</td> <td>RNASEQ-AVF11_S3_R1_001.fastq.gz</td> <td>RNASEQ-AVF11_S3_R2_001.fastq.gz</td> </tr> <tr> <td>Flag-NLS-mut-TDP-43</td> <td>RNASEQ-AVF12</td> <td>RNASEQ-AVF12_S4_R1_001.fastq.gz</td> <td>RNASEQ-AVF12_S4_R2_001.fastq.gz</td> </tr> <tr> <td>Cneg</td> <td>RNASEQ-AVF13</td> <td>RNASEQ-AVF13_S5_R1_001.fastq.gz</td> <td>RNASEQ-AVF13_S5_R2_001.fastq.gz</td> </tr> <tr> <td>Scramble</td> <td>RNASEQ-AVF14</td> <td>RNASEQ-AVF14_S6_R1_001.fastq.gz</td> <td>RNASEQ-AVF14_S6_R2_001.fastq.gz</td> </tr> <tr> <td>Oligos B+C</td> <td>RNASEQ-AVF15</td> <td>RNASEQ-AVF15_S7_R1_001.fastq.gz</td> <td>RNASEQ-AVF15_S7_R2_001.fastq.gz</td> </tr> <tr> <td>Oligos A+B+C</td> <td>RNASEQ-AVF16</td> <td>RNASEQ-AVF16_S8_R1_001.fastq.gz</td> <td>RNASEQ-AVF16_S8_R2_001.fastq.gz</td> </tr> </tbody> </table> <p> </p>
Deep-sequencing of viral genomes from treatment-naive HIV-infected persons shows positive association between intrahost genetic diversity and viral load
<p><strong><span>Background:</span></strong><span> Infection with human immunodeficiency virus type 1 (HIV) typically results from transmission of a small and genetically uniform viral population. Following transmission, the virus population becomes more diverse because of recombination and acquired mutations through genetic drift and selection. Viral intrahost genetic diversity remains a major obstacle to the cure of HIV; however, there is a disagreement whether intrahost viral genetic diversification associates positively or negatively with disease progression and progression markers. Viral load is a key progression marker and understanding its relationship to viral intrahost genetic diversity could help design future strategies for HIV monitoring and treatment.</span></p> <p><span><strong>Methods:</strong> </span><span>We analyzed deep-sequenced viral genomes from 2,650 treatment-naive HIV-infected persons to measure the intrahost genetic diversity of 2,447 genomic codon positions as calculated by Shannon entropy. We tested for associations between viral load (VL) and amino acid (AA) entropy accounting for sex, age, race, duration of infection, and HIV population structure.</span></p> <p><strong><span>Results:</span></strong><span><strong> </strong>We confirmed that the intrahost genetic diversity is highest in the <em>env</em> gene. Furthermore, we showed that mean Shannon entropy is significantly associated with VL, especially in infections of >24 months duration. We identified 16 significant associations between VL (p-value<2.0x10<sup>-5</sup>) and Shannon entropy at AA positions which in our association analysis explained 13% of the variance in VL.</span></p> <p><strong><span>Conclusions: </span></strong><span>Our results elucidate that viral intrahost genetic diversity is associated with VL and could be used as a better disease progression marker than HIV consensus sequence variants, especially in infections of longer duration. We emphasize that viral intrahost diversity should be considered when studying viral genomes and infection outcomes.</span></p>
HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNA
<p>In the absence of antiretroviral therapy (ART), a subset of individuals, termed HIV controllers, have levels of plasma viremia that are orders of magnitude lower than non-controllers who are at higher risk for HIV disease progression. In addition to having fewer infected cells resulting in fewer cells with HIV RNA, it is possible that lower levels of plasma viremia in controllers is due to a lower fraction of the infected cells having HIV-1 unspliced RNA (HIV usRNA) compared with non-controllers. To directly test this possibility, we used sensitive and quantitative single cell sequencing methods to compare the fraction of infected cells that contain one or more copies of HIV usRNA in peripheral blood mononuclear cells (PBMC) obtained from controllers and non-controllers. The fraction of infected cells containing HIV usRNA did not differ between the two groups. Rather, the levels of viremia were strongly associated with the total number of infected cells that had HIV usRNA, as reported by others, with controllers having 34-fold fewer infected cells per million PBMC. These results reveal for the first time that viremic control is not associated with a lower fraction of proviruses expressing HIV usRNA, unlike what is reported for elite controllers, but is only related to having fewer infected cells overall, maybe reflecting greater immune clearance of infected cells. Our findings show that proviral silencing is not a key mechanism for viremic control and will help to refine strategies towards achieving HIV remission without ART.</p>
Supplementary Data for "Convergent evolution as an indicator for selection during acute HIV-1 infection"
<p><strong>Supplementary Data 1. Position of all identified mutations in the <em>env</em> gene. </strong>This file contains detailed information about the identity of the observed mutations. It provides the position in the HXB2 genome, the amino acid change they cause in the different genetic backgrounds and the number of HIV-1 subtypes (out of a total of 170) the mutations occurs in.</p> <p><strong>Supplementary Data 2. Position of all identified mutations in the <em>rev</em> exon part of the <em>env </em>gene. </strong>Same as Supplementary Data 1, except that only mutations and amino acid substitutions in the <em>rev</em> exon 2 are shown.</p> <p><strong>Supplementary Program.</strong> With this program one can redo the analyses and simulations of the manuscript.</p>
Fig. 1 in Infection with Toxoplasma gondii can promote chronic liver diseases in HIV-infected individuals
Fig. 1. Frequency of different liver pathologies in deceased patients from cohorts seropositive and seronegative to Toxoplasma gondii (Nicolle et Manceaux, 1908). * – difference between the indices for the entire cohort of seropositive patients and for the group of deceased patients from this cohort (p <0.05); ^ – difference between the indices for the entire cohort of seronegative patients and for the group of deceased patients from this cohort (p <0.05)
More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents
ClinicalTrials.gov study NCT03497676. IPD Sharing: YES. Countries: 5. Publications: 6.
Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV
ClinicalTrials.gov study NCT00659789. IPD Sharing: NO. Countries: 5. Publications: 1.
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to
ClinicalTrials.gov study NCT01618305. IPD Sharing: YES. Countries: 7. Publications: 1.
HIV And Parasitic Infection (HAPI) Study
ClinicalTrials.gov study NCT05323396. IPD Sharing: YES. Countries: 1. Publications: 3.
A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women
ClinicalTrials.gov study NCT04094870. IPD Sharing: YES. Countries: 1. Publications: 1.
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
ClinicalTrials.gov study NCT03760458. IPD Sharing: YES. Countries: 4. Publications: 2.
A Trial to Compare Antibacterial vs. Placebo Mouthwash to Reduce the Incidence of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men (MSM) Taking HIV Pre-Exposure Prophylaxis (PrEP)
ClinicalTrials.gov study NCT03881007. IPD Sharing: YES. Countries: 1. Publications: 2.
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
ClinicalTrials.gov study NCT01712256. IPD Sharing: NO. Countries: 5. Publications: 5.
IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
ClinicalTrials.gov study NCT01818258. IPD Sharing: NO. Countries: 4. Publications: 2.
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
ClinicalTrials.gov study NCT01704781. IPD Sharing: NO. Countries: 1. Publications: 4.
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
ClinicalTrials.gov study NCT03048422. IPD Sharing: YES. Countries: 9. Publications: 5.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.